Lixte Biotechnology Holdings Management
Management criteria checks 3/4
Lixte Biotechnology Holdings' CEO is John Kovach, appointed in Aug 2005, has a tenure of 18.08 years. total yearly compensation is $315.64K, comprised of 79.2% salary and 20.8% bonuses, including company stock and options. directly owns 12.78% of the company’s shares, worth €669.54K. The average tenure of the management team and the board of directors is 3.1 years and 5.1 years respectively.
Key information
John Kovach
Chief executive officer
US$315.6k
Total compensation
| CEO salary percentage | 79.2% |
| CEO tenure | 18.1yrs |
| CEO ownership | 12.8% |
| Management average tenure | 3.1yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$316k | US$250k | -US$6m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$7m |
| Dec 31 2021 | US$250k | US$250k | -US$7m |
| Sep 30 2021 | n/a | n/a | -US$6m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$108k | US$108k | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$2m |
| Dec 31 2019 | US$60k | US$60k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | US$60k | US$60k | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$2m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | -US$2m |
| Dec 31 2017 | US$60k | US$60k | -US$2m |
| Sep 30 2017 | n/a | n/a | -US$2m |
| Jun 30 2017 | n/a | n/a | -US$2m |
| Mar 31 2017 | n/a | n/a | -US$2m |
| Dec 31 2016 | US$60k | US$60k | -US$2m |
Compensation vs Market: John's total compensation ($USD315.64K) is about average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Kovach (86 yo)
18.1yrs
Tenure
US$315,640
Compensation
Dr. John S. Kovach, M.D, founded Lixte Biotechnology Holdings, Inc. in August 2005 and serves as its Chairman, Chief Executive Officer, and President. He has been Chief Scientific Officer of Lixte Biotechn...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 18.1yrs | US$315.64k | 12.78% € 669.5k | |
| VP & CFO | 3.1yrs | US$240.64k | no data | |
| VP & COO | less than a year | US$244.46k | 2.72% € 142.3k | |
| Chief Medical Officer | 3.1yrs | US$240.64k | no data |
3.1yrs
Average Tenure
73.5yo
Average Age
Experienced Management: 8640's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 18.7yrs | US$315.64k | 12.78% € 669.5k | |
| Member of Scientific Advisory Committee | 9.7yrs | no data | no data | |
| Independent Director | 7.3yrs | US$85.84k | 0.33% € 17.4k | |
| Independent Director | 1.3yrs | US$133.87k | 0.67% € 35.0k | |
| Independent Director | 1.3yrs | US$170.39k | 0.044% € 2.3k | |
| Independent Director | 5.1yrs | US$93.34k | 0.23% € 12.3k | |
| Independent Director | 2.3yrs | US$93.34k | 0.028% € 1.5k |
5.1yrs
Average Tenure
70yo
Average Age
Experienced Board: 8640's board of directors are considered experienced (5.1 years average tenure).